查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
COVID-19 疫苗全球市场（疫苗类型：mRNA、病毒载体疫苗（腺病毒疫苗、灭活病毒疫苗、其他）、其他）——2022-2031 年行业分析、规模、份额、增长、趋势和预测
市场调查报告书
商品编码
1229590

COVID-19 疫苗全球市场（疫苗类型：mRNA、病毒载体疫苗（腺病毒疫苗、灭活病毒疫苗、其他）、其他）——2022-2031 年行业分析、规模、份额、增长、趋势和预测

COVID-19 Vaccine Market (Vaccine Type: mRNA, Viral Vector Vaccines (Adenovirus Vaccines, Inactivated Virus Vaccines, and Others), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 217 Pages | 商品交期: 2-10个工作天内

价格

本报告介绍了 2017 年至 2031 年全球 COVID-19 疫苗市场的收入，基准年为 2022 年，预测年为 2031 年。 它还介绍了 2022 年至 2031 年全球 COVID-19 疫苗市场的复合年增长率 (CAGR %)。

这份报告是广泛研究的结果。 在初步研究中，分析师对主要思想领袖、行业领袖和舆论製造者进行访谈，他们提供了大量的研究工作。 在我们的二次研究中，我们参考了主要参与者的产品文献、年度报告、新闻稿和相关文件，以瞭解 COVID-19 疫苗市场。

该报告深入探讨了全球 COVID-19 疫苗市场的竞争格局。 已经确定了在全球 COVID-19 疫苗市场上运营的主要参与者，并根据各种属性对每家公司进行了介绍。 公司概况、财务状况、近期市场发展和 SWOT 是本报告中描述的全球 COVID-19 疫苗市场参与者的属性。

内容

第一章前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 调查要点

第 2 章假设和研究方法

第 3 章执行摘要：COVID-19 疫苗的全球市场

第 4 章市场概述

  • 介绍
    • COVID-19 疫苗定义
    • 行业的演变和发展
  • 概览
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • 2017-2031 年 COVID-19 疫苗全球市场分析和预测
    • 市场收入预测

第五章市场展望

  • 世界各地疾病的发病率和流行率
  • 全球 COVID-19 疫苗接种状况分析
  • 全球/主要国家/地区的监管情景

第 6 章全球 COVID-19 疫苗市场分析和预测：按疫苗类型分类

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
    • 病毒载体疫苗
      • 灭活​​病毒疫苗
      • 腺病毒疫苗
      • 其他
    • 其他
  • 市场吸引力：按疫苗类型

第 7 章全球 COVID-19 疫苗市场分析和预测：按年龄组分类

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 市场吸引力：按年龄段

第 8 章全球 COVID-19 疫苗市场分析和预测：按分销渠道

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 市场吸引力：按分销渠道

第 9 章全球 COVID-19 疫苗市场分析和预测：按地区

  • 主要发现
  • 市场价值预测：按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按国家/地区

第 10 章北美 COVID-19 疫苗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
    • 病毒载体疫苗
      • 灭活​​病毒疫苗
      • 腺病毒疫苗
      • 其他
    • 其他
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 2017-2031 年各个国家/地区的市场价值预测
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按疫苗类型
    • 按年龄段
    • 按分销渠道
    • 按国家

第 11 章欧洲 COVID-19 疫苗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
    • 病毒载体疫苗
      • 病毒载体疫苗
      • 腺病毒疫苗
      • 其他
    • 其他
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 2017-2031 年各个国家/地区的市场价值预测
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 市场吸引力分析
    • 按疫苗类型
    • 按年龄段
    • 按分销渠道
    • 按国家

第 12 章亚太 COVID-19 疫苗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
    • 病毒载体疫苗
      • 灭活​​病毒疫苗
      • 腺病毒疫苗
      • 其他
    • 其他
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 2017-2031 年各个国家/地区的市场价值预测
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 市场吸引力分析
    • 按疫苗类型
    • 按年龄段
    • 按分销渠道
    • 按国家

第 13 章拉丁美洲 COVID-19 疫苗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
    • 病毒载体疫苗
      • 灭活​​病毒疫苗
      • 腺病毒疫苗
      • 其他
    • 其他
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 2017-2031 年各个国家/地区的市场价值预测
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 市场吸引力分析
    • 按疫苗类型
    • 按年龄段
    • 按分销渠道
    • 按国家

第 14 章中东和非洲 COVID-19 疫苗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年各疫苗类型的市场价值预测
    • 核糖核酸
      • 灭活​​病毒疫苗
      • 腺病毒疫苗
      • 其他
    • 病毒载体疫苗
    • 其他
  • 2017-2031 年按年龄段划分的市场价值预测
    • 12-18 岁
    • 18岁以上
  • 2017-2031 年各分销渠道的市场价值预测
    • 政府机构
    • 医院和诊所
    • 其他
  • 2017-2031 年各个国家/地区的市场价值预测
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区
  • 市场吸引力分析
    • 按疫苗类型
    • 按年龄段
    • 按分销渠道
    • 按国家

第15章竞争格局

  • 市场竞争对手 - 竞争矩阵（按层次结构和公司规模）
  • 各公司的市场份额分析（2021 年）
  • 公司简介
    • Pfizer-BioNTech
    • Moderna
    • AstraZeneca
    • Johnson & Johnson
    • Sinovac
    • Sinopharm
    • Bharat Biotech
    • Serum Institute of India
    • Novavax
    • Gamaleya Research Institute
    • CanSino Biologics
    • CureVac
    • GlaxoSmithKline
    • Sanofi-GSK
Product Code: TMRGL81871

The report provides revenue of the global COVID-19 vaccine market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 vaccine market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the COVID-19 vaccine market.

The report delves into the competitive landscape of the global COVID-19 vaccine market. Key players operating in the global COVID-19 vaccine market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 vaccine market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global COVID-19 Vaccine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. COVID-19 vaccine Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

  • 5.1. Disease incidence and prevalence across the globe
  • 5.2. Analysis of COVID-19 vaccination across the globe
  • 5.3. Regulatory scenario across the globe/key countries

6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine Type, 2017-2031
    • 6.3.1. mRNA
    • 6.3.2. Viral Vector Vaccines
      • 6.3.2.1. Inactivated Virus Vaccines
      • 6.3.2.2. Adenovirus Vaccines
      • 6.3.2.3. Others
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Vaccine Type

7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Age Group, 2017-2031
    • 7.3.1. 12 to 18
    • 7.3.2. Above 18
  • 7.4. Market Attractiveness, by Age Group

8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Government Entities
    • 8.3.2. Hospitals and Clinics
    • 8.3.3. Others
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Country/Region

10. North America COVID-19 Vaccine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Vaccine Type, 2017-2031
    • 10.2.1. mRNA
    • 10.2.2. Viral Vector Vaccines
      • 10.2.2.1. Inactivated Virus Vaccines
      • 10.2.2.2. Adenovirus Vaccines
      • 10.2.2.3. Others
    • 10.2.3. Others
  • 10.3. Market Value Forecast, by Age Group, 2017-2031
    • 10.3.1. 12 to 18
    • 10.3.2. Above 18
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Government Entities
    • 10.4.2. Hospitals and Clinics
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Vaccine Type
    • 10.6.2. By Age Group
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe COVID-19 Vaccine Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Vaccine Type , 2017-2031
    • 11.2.1. mRNA
    • 11.2.2. Viral Vector Vaccines
      • 11.2.2.1. Viral Vector Vaccines
      • 11.2.2.2. Adenovirus Vaccines
      • 11.2.2.3. Others
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Age Group, 2017-2031
    • 11.3.1. 12 to 18
    • 11.3.2. Above 18
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Government Entities
    • 11.4.2. Hospitals and Clinics
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country, 2017-2031
    • 11.5.1. U.K.
    • 11.5.2. Germany
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Vaccine Type
    • 11.6.2. By Age Group
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Vaccine Type, 2017-2031
    • 12.2.1. mRNA
    • 12.2.2. Viral Vector Vaccines
      • 12.2.2.1. Inactivated Virus Vaccines
      • 12.2.2.2. Adenovirus Vaccines
      • 12.2.2.3. Others
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Age Group, 2017-2031
    • 12.3.1. 12 to 18
    • 12.3.2. Above 18
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Government Entities
    • 12.4.2. Hospitals and Clinics
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Vaccine Type
    • 12.6.2. By Age Group
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Latin America COVID-19 Vaccine Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Vaccine Type, 2017-2031
    • 13.2.1. mRNA
    • 13.2.2. Viral Vector Vaccines
      • 13.2.2.1. Inactivated Virus Vaccines
      • 13.2.2.2. Adenovirus Vaccines
      • 13.2.2.3. Others
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Age Group, 2017-2031
    • 13.3.1. 12 to 18
    • 13.3.2. Above 18
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Government Entities
    • 13.4.2. Hospitals and Clinics
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Vaccine Type
    • 13.6.2. By Age Group
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Vaccine Type, 2017-2031
    • 14.2.1. mRNA
      • 14.2.1.1. Inactivated Virus Vaccines
      • 14.2.1.2. Adenovirus Vaccines
      • 14.2.1.3. Others
    • 14.2.2. Viral Vector Vaccines
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Age Group, 2017-2031
    • 14.3.1. 12 to 18
    • 14.3.2. Above 18
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Government Entities
    • 14.4.2. Hospitals and Clinics
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country, 2017-2031
    • 14.5.1. GCC countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Vaccine Type
    • 14.6.2. By Age Group
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer-BioNTech
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Vaccine Type Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Moderna
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Vaccine Type Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AstraZeneca
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Vaccine Type Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Johnson & Johnson
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Vaccine Type Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Sinovac
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Vaccine Type Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Sinopharm
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Vaccine Type Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Bharat Biotech
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Vaccine Type Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Serum Institute of India
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Vaccine Type Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Novavax
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Vaccine Type Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Gamaleya Research Institute
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Vaccine Type Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. CanSino Biologics
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Vaccine Type Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. CureVac
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Vaccine Type Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview
    • 15.3.13. GlaxoSmithKline
      • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.13.2. Vaccine Type Portfolio
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. SWOT Analysis
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Sanofi-GSK
      • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.14.2. Vaccine Type Portfolio
      • 15.3.14.3. Financial Overview
      • 15.3.14.4. SWOT Analysis
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017-2031
  • Table 02: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 03: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 04: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 05: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 07: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017-2031
  • Table 08: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 09: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 10: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 11: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 13: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type , 2017-2031
  • Table 14: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 15: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 16: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 17: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 19: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017-2031
  • Table 20: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 21: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 22: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 23: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 25: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017-2031
  • Table 26: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 27: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 28: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 29: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 31: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017-2031
  • Table 32: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017-2031
  • Table 33: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017-2031
  • Table 34: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 35: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 36: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031

List of Figures

  • Figure 01: Global COVID-19 Vaccine Market
  • Figure 02: Global COVID-19 Vaccine Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 03: Market Value Share, by Vaccine Type (2021)
  • Figure 04: Market Value Share, by Age Group (2021)
  • Figure 05: Market Value Share, by Distribution Channel (2021)
  • Figure 06: Market Value Share, by Region (2021)
  • Figure 07: Global COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 08 Global COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021-2031
  • Figure 09: Global COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 10: Global COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 11: Global COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 12: Global COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 13: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 14: Global COVID-19 Vaccine Market Value Share, by Region, 2021-2031
  • Figure 15: Global COVID-19 Vaccine Market Attractiveness, by Region, 2021-2031
  • Figure 16: North America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 17: North America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021-2031
  • Figure 18: North America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 19: North America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 20: North America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 21: North America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 22: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 23: North America COVID-19 Vaccine Market Value Share, by Country, 2021-2031
  • Figure 24: North America COVID-19 Vaccine Market Attractiveness, by Country, 2021-2031
  • Figure 25: Europe COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 26: Europe COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021-2031
  • Figure 27: Europe COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 28: Europe COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 29: Europe COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 30: Europe COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 31: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 32: Europe COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021-2031
  • Figure 33: Europe COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021-2031
  • Figure 34: Asia Pacific COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 35: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021-2031
  • Figure 36: Asia Pacific COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 37: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 38: Asia Pacific COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 39: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 40: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 41: Asia Pacific COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021-2031
  • Figure 42: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021-2031
  • Figure 43: Latin America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 44: Latin America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021-2031
  • Figure 45: Latin America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 46: Latin America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 47: Latin America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 48: Latin America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 49: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 50: Latin America COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021-2031
  • Figure 51: Latin America COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021-2031
  • Figure 52: Middle East & Africa COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
  • Figure 53: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Vaccine Type, 2021-2031
  • Figure 54: Middle East & Africa COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
  • Figure 55: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Age Group, 2021-2031
  • Figure 56: Middle East & Africa COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 57: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021-2031
  • Figure 58: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 59: Middle East & Africa COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021-2031
  • Figure 60: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021-2031
  • Figure 61: Global COVID-19 Vaccine Market Share Analysis, by Company, 2021 (Estimated)
  • Figure 62: Global COVID-19 Vaccine Market Performance, by Company, 2021
  • Figure 63: Competition Matrix